

Claims

1 1. A process for determining IL-10 promoter alleles specific to an
2 individual human, said process comprising the step of: genotyping DNA
3 encoding IL-10 -1.2 to -4.0 kb for a single nucleotide polymorphism, said DNA
4 being obtained from said individual human.

1 2. The process of claim 1 wherein said single nucleotide
2 polymorphism affects IL-10 production.

1 3. A process of predicting a human immunoresponse to a disease,
2 said process comprising the steps of:
3 establishing a correlation between an IL-10 promoter genotype in
4 clinical outcome of said disease;
5 genotyping for an IL-10 promoter to yield a patient IL-10 promoter
6 genotype;
7 comparing said IL-10 promoter genotype with said patient genotype;
8 and
9 determining clinical outcome for said patient based on said patient IL-
10 10 promoter genotype.

1 4. The process of claim 1 wherein said single nucleotide
2 polymorphism is in nucleotide -3575.

1 5. The process of claim 1 wherein said single nucleotide
2 polymorphism is in nucleotide -2849.

1 6. The process of claim 1 wherein said single nucleotide
2 polymorphism is in nucleotide -2763.

1 7. The use of a single nucleotide polymorphism in an IL-10
2 promoter genotype to identify individual susceptibility to a disease.

1 8. The use of claim 7 wherein said disease is selected from the
2 group consisting of: cancer, viral infection, bacterial infection, systemic lupus
3 erythematosus, systemic vasculitis, Felty's syndrome, allergy, asthma,
4 myasthenia gravis, transplant rejection, rheumatoid arthritis, systemic sclerosis,
5 glomerulonephritis, Sjogren's syndrome and inflammatory bowel disease.

1 9. A commercial package comprising reagents for identifying a
2 single nucleotide polymorphism in an IL-10 promoter genotype or phenotype
3 together with instructions for the use thereof as a test to identify individual
4 susceptibility to a disease.

1 10. A diagnostic for disease susceptibility comprising: an IL-10
2 promoter region -1.2 to -4.0 kb having a single nucleotide polymorphism
3 therein.

1 11. The diagnostic of claim 10 wherein the single nucleotide
2 polymorphism is selected from the group consisting of: -3575 T/A, -2849 G/A
3 and -2763 C/A.